Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications.
https://finance.yahoo.com/news/twist-bioscience-kriya-sign-agreement-130000094.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.